TraMagĀ® Plus application successfully submitted to the URPL

We are proud to announce that on November 10, 2022, we successfully submitted an application to the URPL for market authorization of the medicinal product TraMagĀ® Plus in Poland. At the same time on October 25 we received the expected response to our pre-IND submitted to theĀ FDAĀ in early 2022. These next milestones will allow us to further develop our plans for TraMagĀ® Plus in EU and US.
Thanks to our Partners fromĀ SciencePharma,Ā MEDICOFARMA S.A. Contract ManufacturerĀ andĀ Premier Consulting

 

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram